Summit Therapeutics (SMMT) announced that the FDA has accepted for filing Summit’s biologics license application seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous non-small cell lung cancer post-tyrosine kinase inhibitor therapy. The FDA provided a Prescription Drug User Fee Act goal action date of November 14.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Crescent Biopharma initiated with a Buy at Guggenheim
- Summit Therapeutics Advances Ivonescimab Into Key Phase 3 Test in Metastatic Colorectal Cancer
- Biotech Alert: Searches spiking for these stocks today
- Summit Therapeutics: Ivonescimab OS Readout, Regulatory Milestones, and GSK Partnership Underpin Reaffirmed Buy and $40 Target
- Summit Therapeutics Expands Ivonescimab Program With GSK Collaboration